

10. **Petrelli F, Coinu A, Cabiddu M, et al.** Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. *Eur Urol.* 2014 Feb; 65(2): 350–7. doi: 1.1016/j.eururo.2013. 06. 049.
11. **Hermans TJ, Fransen van de Putte EE, et al.** Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer-Results of a nationwide population-based study. *Eur J Cancer.* 2016; 69: 1-8. doi: 10.1016/j.ejca.2016. 09. 015.
12. **Herr HW, Faulkner JR, Grossman HB, et al.** Surgical factors influence bladder cancer outcomes: a co-operative group report. *J Clin Oncol* 2004; 22(14): 2781–2789.
13. **Gschwend JE, Heck MM, Lehmann J, et al.** Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. *Eur Urol.* 2019 Apr; 75(4): 604–611. doi: 10.1016/j.eururo.2018. 09. 047.
14. **Sternberg CN, de Mulder PH, Schornagel JH, et al.** Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organisation for Research and Treatment of Cancer Protocol No. 30924 *J Clin Oncol.* 2021; 19: 2638– 2646.
15. **Pfister C, Gravis G, Fléchon A, et al.** VESPER Trial Investigators. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. *J Clin Oncol.* 2022 Jun 20; 40(18): 2013–2022. doi: 10.1200/JCO.21.02051.
16. **Necchi A, Anichini A, Raggi D, et al.** Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. *J Clin Oncol.* 2018; 36: 3353.
17. **Powles T, Kockx M, Rodriguez-Vida A, et al.** Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. *Nat Med.* 2019; 25: 1706.
18. **Powles TB, PerezValderamma B, Gupta S, et al.** EV-302/KEYNOTE-A39: Open-label, randomized phase 3 study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). *ESMO Congress.* 2023; Abstract LBA6.
19. **Crozier J, Papa N, Perera M, et al.** Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. *World J Urol.* 2019 Apr; 37(4): 667–690. doi: 10.1007/s00345-018-2439-8.